AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 150 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $577,000 | -38.6% | 30,000 | -5.7% | 0.09% | +42.9% |
| Q2 2019 | $940,000 | +6.3% | 31,800 | +71.0% | 0.06% | -26.7% |
| Q1 2019 | $884,000 | +31.7% | 18,600 | 0.0% | 0.09% | -36.8% |
| Q4 2018 | $671,000 | -41.4% | 18,600 | 0.0% | 0.14% | +78.9% |
| Q3 2018 | $1,145,000 | -8.8% | 18,600 | 0.0% | 0.08% | -32.7% |
| Q2 2018 | $1,256,000 | -7.4% | 18,600 | -25.6% | 0.11% | -13.7% |
| Q1 2018 | $1,356,000 | -50.7% | 25,000 | -45.7% | 0.13% | -51.3% |
| Q4 2017 | $2,749,000 | +13.6% | 46,000 | -7.6% | 0.27% | -47.3% |
| Q3 2017 | $2,420,000 | -25.7% | 49,800 | -19.6% | 0.51% | -36.6% |
| Q2 2017 | $3,256,000 | -15.5% | 61,959 | -27.1% | 0.80% | -30.1% |
| Q1 2017 | $3,853,000 | -24.3% | 84,959 | -36.8% | 1.15% | -71.6% |
| Q4 2016 | $5,091,000 | +0.3% | 134,500 | 0.0% | 4.06% | +104.8% |
| Q3 2016 | $5,076,000 | +412.7% | 134,500 | +139.2% | 1.98% | +366.4% |
| Q2 2016 | $990,000 | -69.9% | 56,225 | -58.4% | 0.42% | -13.6% |
| Q4 2015 | $3,287,000 | +164.7% | 135,000 | +92.9% | 0.49% | -42.2% |
| Q3 2015 | $1,242,000 | – | 70,000 | – | 0.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |